Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors

Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors

Herein a novel series of histone deacetylases (HDACs) and epidermal growth factor receptor (EGFR) dual inhibitors were designed and synthesized based on the structure of the approved EGFR inhibitor osimertinib (AZD9291). Among them, four compounds <b>5D</b>, <b>5E</b>, <b&...

Full description

Bibliographic Details
Main Authors:	Hang Dong, Hao Yin, Chunlong Zhao, Jiangying Cao, Wenfang Xu, Yingjie Zhang
Format:	Article
Language:	English
Published:	MDPI AG 2019-06-01
Series:	Molecules
Subjects:	HDAC EGFR multi-target inhibitor antitumor
Online Access:	https://www.mdpi.com/1420-3049/24/13/2407

Similar Items

Design, Synthesis, and Biological Evaluation of Dual c-Met/HDAC Inhibitors Bearing 2-Aminopyrimidine Scaffold
by: Qingwei Zhang, et al.
Published: (2020-09-01)

Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors
by: Tarek S. Ibrahim, et al.
Published: (2021-11-01)

Human EGFR-2, EGFR and HDAC triple-inhibitor CUDC-101 enhances radiosensitivity of GBM cells
by: Cody D Schlaff, et al.
Published: (2015-01-01)

Quinazolinone-Amino Acid Hybrids as Dual Inhibitors of EGFR Kinase and Tubulin Polymerization
by: Mohamed F. Zayed, et al.
Published: (2018-07-01)

Discovery of Indole-Containing Benzamide Derivatives as HDAC1 Inhibitors with In Vitro and In Vivo Antitumor Activities
by: Xiu Gu, et al.
Published: (2022-06-01)

Dual Inhibitors Targeting DNA and Histone Deacetylases
by: Chen Chen, et al.
Published: (2020-06-01)

Design, synthesis and antitumor activity of 5-trifluoromethylpyrimidine derivatives as EGFR inhibitors
by: Yaqing Zuo, et al.
Published: (2022-12-01)

Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities
by: Feifei Yang, et al.
Published: (2019-07-01)

Design, Synthesis, and Evaluation of Benzoheterocyclic-Containing Derivatives as Novel HDAC1 Inhibitors
by: Min-Ru Jiao, et al.
Published: (2022-03-01)

Anticancer Activity and Mechanisms of Action of New Chimeric EGFR/HDAC-Inhibitors
by: Nils Goehringer, et al.
Published: (2021-08-01)

Discovery of YS-363 as a highly potent, selective, and orally eﬃcacious EGFR inhibitor
by: Pengxing He, et al.
Published: (2023-11-01)

Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase 1 (HDAC1) Dual Inhibitors Derived from the Natural Product Saprorthoquinone
by: Yang Lin, et al.
Published: (2020-09-01)

Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma
by: Xiaopeng Peng, et al.
Published: (2023-12-01)

Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights
by: Al-Warhi T, et al.
Published: (2022-05-01)

Synthesis and Evaluation of C15 Triene Urushiol Derivatives as Potential Anticancer Agents and HDAC2 Inhibitor
by: Zhiwen Qi, et al.
Published: (2018-05-01)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
by: Ehab Ghazy, et al.
Published: (2022-01-01)

Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents
by: Sudong Liang, et al.
Published: (2023-12-01)

Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs
by: Wang Y, et al.
Published: (2017-05-01)

Design, Synthesis, and Antiproliferative Activity of Selective Histone Deacetylases 6 Inhibitors Containing a Tetrahydropyridopyrimidine Scaffold
by: Bin Wang, et al.
Published: (2023-10-01)

HDAC6 promotes aggressive development of liver cancer by improving egfr mRNA stability
by: Hong-Ying Dai, et al.
Published: (2023-01-01)

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
by: Christian Mayr, et al.
Published: (2021-07-01)

The Role of HDACs and HDACi in Cartilage and Osteoarthritis
by: He Zhang, et al.
Published: (2020-09-01)

HDAC Inhibition to Prime Immune Checkpoint Inhibitors
by: Edith Borcoman, et al.
Published: (2021-12-01)

EGFR–c-Src-Mediated HDAC3 Phosphorylation Exacerbates Invasion of Breast Cancer Cells
by: Sung-Min Kwak, et al.
Published: (2019-08-01)

Novel dual-targeting inhibitors of NSD2 and HDAC2 for the treatment of liver cancer: structure-based virtual screening, molecular dynamics simulation, and in vitro and in vivo biological activity evaluations
by: Xing Jin, et al.
Published: (2024-12-01)

Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety
by: Al-Sanea MM, et al.
Published: (2020-02-01)

Discovery of BRAF/HDAC Dual Inhibitors Suppressing Proliferation of Human Colorectal Cancer Cells
by: Yingjun Li, et al.
Published: (2022-07-01)

A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
by: Anna Fontana, et al.
Published: (2022-09-01)

Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications
by: Nina Shaban, et al.
Published: (2023-12-01)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
by: Laurence Booth, et al.
Published: (2019-07-01)

Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy
by: Nisha Holay, et al.
Published: (2023-09-01)

Pathological Role of HDAC8: Cancer and Beyond
by: Ji Yoon Kim, et al.
Published: (2022-10-01)

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
by: Yufeng Li, et al.
Published: (2023-04-01)

Design, synthesis and biological evaluation of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors for the treatment of ALK addicted cancer
by: Dafeng Guo, et al.
Published: (2022-12-01)

Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells
by: Christian Schrenk, et al.
Published: (2023-03-01)

HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities
by: Emily Koeneke, et al.
Published: (2015-04-01)

HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action
by: Yoichi Imai, et al.
Published: (2019-04-01)

Potential Therapeutic Role of HDAC Inhibitors in FUS-ALS
by: Clara Tejido, et al.
Published: (2021-08-01)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
by: Elizabeth A. Thomas
Published: (2014-05-01)

Methionine 274 Is Not the Determining Factor for Selective Inhibition of Histone Deacetylase 8 (HDAC8) by L-Shaped Inhibitors
by: Niklas Jänsch, et al.
Published: (2022-10-01)